TRPC6 CRISPR/Cas9 KO Plasmid (h): sc-401205
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TRPC6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TRPC6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TRPC6 Antibody (B-10): sc-515837
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRPC6 CRISPR/Cas9 KO Plasmid (h) | sc-401205 | 20 µg | $397.00 |
Overview
TRPC6 encodes a non-selective cation channel of the transient receptor potential canonical family that mediates receptor-operated Ca²⁺ influx at the plasma membrane. Channel activity is commonly coupled to PLC-driven signaling downstream of GPCRs and receptor tyrosine kinases, shaping cytosolic Ca²⁺ dynamics that regulate transcriptional responses, cytoskeletal remodeling, and cell motility. In human tissues, TRPC6 contributes to mechanosensitive and diacylglycerol-responsive calcium entry with downstream engagement of pathways such as calcineurin–NFAT and MAPK signaling. Dysregulated TRPC6 function has been implicated in kidney podocyte biology and glomerular disease mechanisms, as well as cardiovascular and neuroinflammatory processes, supporting its utility as a target for pathway dissection in cell-based models.
TRPC6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TRPC6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TRPC6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TRPC6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TRPC6 protein expression.
This CRISPR knockout system enables efficient generation of TRPC6-deficient cell models for investigation of TRPC6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TRPC6 exon(s) critical for TRPC6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TRPC6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TRPC6 CRISPR/Cas9 KO Plasmid (h) and TRPC6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TRPC6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TRPC6 HDR Plasmid (h) and TRPC6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TRPC6 homology arms to support homology-directed repair at defined TRPC6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.